Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:PD 0325901
go back to main search page
Accession:CHEBI:88249 term browser browse the term
Definition:A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).
Synonyms:exact_synonym: N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
 related_synonym: Formula=C16H14F3IN2O4;   InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1;   InChIKey=SUDAHWBOROXANE-SECBINFHSA-N;   PD-325901;   PD0325901;   SMILES=C1(=CC=C(C(=C1NC=2C(=CC(=CC2)I)F)F)F)C(NOC[C@@H](CO)O)=O
 xref: CAS:391210-10-9;   LINCS:LSM-1101
 xref_mesh: MESH:C506614
 xref: PMID:16944149;   PMID:18651802;   PMID:18952427;   PMID:19929595;   PMID:20215549;   PMID:20332327;   PMID:20587665;   PMID:21516509;   PMID:22752429;   PMID:24269278;   PMID:25031379;   PMID:25195567;   PMID:25798061;   PMID:25907661;   PMID:25977343;   Reaxys:11343179


show annotations for term's descendants           Sort by:
PD 0325901 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ACACA acetyl-CoA carboxylase alpha multiple interactions ISO mirdametinib inhibits the reaction [polyphyllin I inhibits the reaction [Dietary Fats results in increased expression of ACACA protein]] CTD PMID:36120828 NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836 		JBrowse link
G ADAM19 ADAM metallopeptidase domain 19 decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of ADAM19 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ADAM19 mRNA		 CTD PMID:25119042 NCBI chr 5:157,477,304...157,575,775
Ensembl chr 5:157,395,534...157,575,775 		JBrowse link
G ADAMTS6 ADAM metallopeptidase with thrombospondin type 1 motif 6 multiple interactions EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ADAMTS6 mRNA CTD PMID:25119042 NCBI chr 5:65,148,738...65,481,920
Ensembl chr 5:65,148,738...65,481,920 		JBrowse link
G AKAP12 A-kinase anchoring protein 12 decreases expression EXP mirdametinib results in decreased expression of AKAP12 mRNA CTD PMID:25119042 NCBI chr 6:151,239,967...151,358,559
Ensembl chr 6:151,239,967...151,358,559 		JBrowse link
G AKT1 AKT serine/threonine kinase 1 multiple interactions
increases phosphorylation		 EXP [mirdametinib co-treated with MK 2206] results in increased phosphorylation of AKT1 protein; [mirdametinib co-treated with silmitasertib] results in decreased phosphorylation of AKT1 protein; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of AKT1 protein]; romidepsin inhibits the reaction [[mirdametinib co-treated with MK 2206] results in increased phosphorylation of AKT1 protein]
mirdametinib results in increased phosphorylation of AKT1 protein		 CTD PMID:22415236 PMID:25798061 PMID:27634878 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759 		JBrowse link
G ALB albumin decreases expression ISO mirdametinib results in decreased expression of ALB protein CTD PMID:21976371 NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482 		JBrowse link
G ANK3 ankyrin 3 multiple interactions EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ANK3 mRNA CTD PMID:25119042 NCBI chr10:60,026,298...60,733,528
Ensembl chr10:60,026,298...60,733,490 		JBrowse link
G ANO1 anoctamin 1 decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of ANO1 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ANO1 mRNA		 CTD PMID:25119042 NCBI chr11:69,965,997...70,189,530
Ensembl chr11:69,985,907...70,189,530 		JBrowse link
G ANPEP alanyl aminopeptidase, membrane decreases expression EXP mirdametinib results in decreased expression of ANPEP mRNA CTD PMID:25119042 NCBI chr15:89,784,895...89,814,852
Ensembl chr15:89,784,895...89,815,401 		JBrowse link
G ARHGAP24 Rho GTPase activating protein 24 multiple interactions EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ARHGAP24 mRNA CTD PMID:25119042 NCBI chr 4:85,475,150...86,002,666
Ensembl chr 4:85,475,150...86,002,668 		JBrowse link
G ARL4C ADP ribosylation factor like GTPase 4C decreases expression EXP mirdametinib results in decreased expression of ARL4C mRNA CTD PMID:25119042 NCBI chr 2:234,493,041...234,497,081
Ensembl chr 2:234,493,041...234,497,081 		JBrowse link
G BAK1 BCL2 antagonist/killer 1 increases expression
multiple interactions		 EXP mirdametinib results in increased expression of BAK1 protein
[mirdametinib co-treated with MK 2206] results in increased expression of BAK1 protein; [romidepsin co-treated with mirdametinib co-treated with MK 2206] results in increased expression of BAK1 protein; [romidepsin co-treated with mirdametinib] results in increased expression of BAK1 protein		 CTD PMID:27634878 NCBI chr 6:33,572,552...33,580,276
Ensembl chr 6:33,572,547...33,580,293 		JBrowse link
G BCL2L11 BCL2 like 11 increases expression
multiple interactions		 EXP mirdametinib results in increased expression of BCL2L11 protein
[mirdametinib co-treated with MK 2206] results in increased expression of BCL2L11 protein; [romidepsin co-treated with mirdametinib co-treated with MK 2206] results in increased expression of BCL2L11 protein; [romidepsin co-treated with mirdametinib] results in increased expression of BCL2L11 protein; KRAS protein affects the reaction [mirdametinib results in increased expression of BCL2L11 protein]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [mirdametinib results in increased expression of BCL2L11 protein]]; NVP-BKM120 promotes the reaction [mirdametinib results in increased expression of BCL2L11 protein]		 CTD PMID:24576621 PMID:27634878 NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,444 		JBrowse link
G BID BH3 interacting domain death agonist multiple interactions ISO [mirdametinib co-treated with MK 2206] results in increased expression of BID mRNA; [mirdametinib co-treated with MK 2206] results in increased expression of BID protein modified form CTD PMID:28691888 NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770 		JBrowse link
G BIRC3 baculoviral IAP repeat containing 3 multiple interactions EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of BIRC3 mRNA CTD PMID:25119042 NCBI chr11:102,317,484...102,339,403
Ensembl chr11:102,317,484...102,339,403 		JBrowse link
G CCL20 C-C motif chemokine ligand 20 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of CCL20 mRNA
mirdametinib results in decreased expression of CCL20 mRNA		 CTD PMID:25119042 NCBI chr 2:227,813,842...227,817,556
Ensembl chr 2:227,805,739...227,817,564 		JBrowse link
G CCND1 cyclin D1 multiple interactions ISO mirdametinib inhibits the reaction [camostat results in increased expression of CCND1 protein] CTD PMID:25104499 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474 		JBrowse link
G CCND3 cyclin D3 multiple interactions ISO mirdametinib inhibits the reaction [camostat results in increased expression of CCND3 protein] CTD PMID:25104499 NCBI chr 6:41,934,933...42,050,035
Ensembl chr 6:41,934,934...42,050,357 		JBrowse link
G CCNE1 cyclin E1 multiple interactions ISO mirdametinib inhibits the reaction [camostat results in increased expression of CCNE1 protein] CTD PMID:25104499 NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312 		JBrowse link
G CPT1C carnitine palmitoyltransferase 1C multiple interactions ISO mirdametinib inhibits the reaction [polyphyllin I inhibits the reaction [Dietary Fats results in decreased expression of CPT1C protein]] CTD PMID:36120828 NCBI chr19:49,690,662...49,713,731
Ensembl chr19:49,690,898...49,713,731 		JBrowse link
G CXCL1 C-X-C motif chemokine ligand 1 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of CXCL1 mRNA
mirdametinib results in decreased expression of CXCL1 mRNA		 CTD PMID:25119042 NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308 		JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of CXCL8 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of CXCL8 mRNA		 CTD PMID:25119042 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716 		JBrowse link
G CYB5R2 cytochrome b5 reductase 2 multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of CYB5R2 mRNA
mirdametinib results in decreased expression of CYB5R2 mRNA		 CTD PMID:25119042 NCBI chr11:7,665,095...7,674,267
Ensembl chr11:7,665,100...7,677,222 		JBrowse link
G CYP24A1 cytochrome P450 family 24 subfamily A member 1 decreases expression
increases expression		 ISO mirdametinib results in decreased expression of CYP24A1 mRNA
mirdametinib results in increased expression of CYP24A1 mRNA		 CTD PMID:21976371 PMID:23872713 NCBI chr20:54,143,538...54,173,986
Ensembl chr20:54,153,446...54,173,986 		JBrowse link
G CYP27B1 cytochrome P450 family 27 subfamily B member 1 increases expression ISO mirdametinib results in increased expression of CYP27B1 mRNA CTD PMID:21976371 NCBI chr12:57,762,334...57,767,078
Ensembl chr12:57,762,334...57,768,986 		JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 increases expression EXP mirdametinib results in increased expression of CYP3A4 mRNA CTD PMID:24819614 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248 		JBrowse link
G CYP3A5 cytochrome P450 family 3 subfamily A member 5 increases expression EXP mirdametinib results in increased expression of CYP3A5 mRNA CTD PMID:24819614 NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996 		JBrowse link
G CYP3A7 cytochrome P450 family 3 subfamily A member 7 increases expression EXP mirdametinib results in increased expression of CYP3A7 mRNA CTD PMID:24819614 NCBI chr 7:99,705,036...99,735,196
Ensembl chr 7:99,705,036...99,735,196 		JBrowse link
G DCBLD2 discoidin, CUB and LCCL domain containing 2 decreases expression EXP mirdametinib results in decreased expression of DCBLD2 mRNA CTD PMID:25119042 NCBI chr 3:98,795,941...98,901,695
Ensembl chr 3:98,795,941...98,901,695 		JBrowse link
G DNMBP dynamin binding protein decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of DNMBP mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of DNMBP mRNA		 CTD PMID:25119042 NCBI chr10:99,875,571...100,009,947
Ensembl chr10:99,875,577...100,009,947 		JBrowse link
G DOCK4 dedicator of cytokinesis 4 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of DOCK4 mRNA
mirdametinib results in decreased expression of DOCK4 mRNA		 CTD PMID:25119042 NCBI chr 7:111,726,110...112,206,399
Ensembl chr 7:111,726,110...112,206,407 		JBrowse link
G DUSP4 dual specificity phosphatase 4 decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of DUSP4 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of DUSP4 mRNA		 CTD PMID:25119042 NCBI chr 8:29,333,064...29,350,684
Ensembl chr 8:29,333,064...29,350,684 		JBrowse link
G DUSP6 dual specificity phosphatase 6 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of DUSP6 mRNA
mirdametinib results in decreased expression of DUSP6 mRNA		 CTD PMID:25119042 NCBI chr12:89,347,235...89,352,501
Ensembl chr12:89,347,235...89,352,501 		JBrowse link
G EFNA5 ephrin A5 multiple interactions EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of EFNA5 mRNA CTD PMID:25119042 NCBI chr 5:107,376,894...107,670,937
Ensembl chr 5:107,376,894...107,670,937 		JBrowse link
G EGR1 early growth response 1 decreases expression
multiple interactions		 ISO mirdametinib results in decreased expression of EGR1 mRNA
mirdametinib inhibits the reaction [camostat results in increased expression of EGR1 mRNA]		 CTD PMID:21976371 PMID:25104499 NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303 		JBrowse link
G EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions EXP [Ku 0063794 co-treated with mirdametinib] results in decreased phosphorylation of EIF4EBP1 protein; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein] CTD PMID:22415236 NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365 		JBrowse link
G EMP1 epithelial membrane protein 1 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of EMP1 mRNA
mirdametinib results in decreased expression of EMP1 mRNA		 CTD PMID:25119042 NCBI chr12:13,196,726...13,219,941
Ensembl chr12:13,196,723...13,219,941 		JBrowse link
G ERCC1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
decreases expression		 EXP mirdametinib inhibits the reaction [Cisplatin results in increased expression of ERCC1 mRNA]; mirdametinib inhibits the reaction [Cisplatin results in increased expression of ERCC1 protein]
mirdametinib results in decreased expression of ERCC1 mRNA		 CTD PMID:21996734 NCBI chr19:45,407,334...45,451,547
Ensembl chr19:45,407,334...45,478,828 		JBrowse link
G ERCC4 ERCC excision repair 4, endonuclease catalytic subunit increases expression EXP mirdametinib results in increased expression of ERCC4 mRNA CTD PMID:21996734 NCBI chr16:13,920,154...13,952,348
Ensembl chr16:13,920,138...13,952,348 		JBrowse link
G ESM1 endothelial cell specific molecule 1 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ESM1 mRNA
mirdametinib results in decreased expression of ESM1 mRNA		 CTD PMID:25119042 NCBI chr 5:54,977,867...54,985,593
Ensembl chr 5:54,977,867...55,022,671 		JBrowse link
G ETS1 ETS proto-oncogene 1, transcription factor multiple interactions EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ETS1 mRNA CTD PMID:25119042 NCBI chr11:128,458,765...128,587,558
Ensembl chr11:128,458,761...128,587,558 		JBrowse link
G ETV1 ETS variant transcription factor 1 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ETV1 mRNA
mirdametinib results in decreased expression of ETV1 mRNA		 CTD PMID:25119042 NCBI chr 7:13,891,229...13,991,425
Ensembl chr 7:13,891,229...13,991,425 		JBrowse link
G ETV4 ETS variant transcription factor 4 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ETV4 mRNA
mirdametinib results in decreased expression of ETV4 mRNA		 CTD PMID:25119042 NCBI chr17:43,527,846...43,546,340
Ensembl chr17:43,527,844...43,579,620 		JBrowse link
G ETV5 ETS variant transcription factor 5 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ETV5 mRNA
mirdametinib results in decreased expression of ETV5 mRNA		 CTD PMID:25119042 NCBI chr 3:186,046,314...186,109,089
Ensembl chr 3:186,046,314...186,110,318 		JBrowse link
G FASN fatty acid synthase multiple interactions EXP mirdametinib inhibits the reaction [Protein Kinase Inhibitors inhibits the reaction [FASN protein results in increased expression of UCP1 protein]] CTD PMID:26670611 NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294 		JBrowse link
G FGF23 fibroblast growth factor 23 multiple interactions ISO mirdametinib inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK3 protein]; mirdametinib results in increased expression of and results in increased secretion of FGF23 protein CTD PMID:23872713 NCBI chr12:4,368,227...4,379,712
Ensembl chr12:4,368,227...4,379,712 		JBrowse link
G FMNL2 formin like 2 decreases expression EXP mirdametinib results in decreased expression of FMNL2 mRNA CTD PMID:25119042 NCBI chr 2:152,335,174...152,649,826
Ensembl chr 2:152,335,174...152,649,826 		JBrowse link
G FOS Fos proto-oncogene, AP-1 transcription factor subunit decreases expression
multiple interactions		 ISO mirdametinib results in decreased expression of FOS mRNA
mirdametinib inhibits the reaction [camostat results in increased expression of FOS mRNA]		 CTD PMID:21976371 PMID:25104499 NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230 		JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of FOSL1 protein
[mirdametinib co-treated with silmitasertib] results in decreased expression of FOSL1 protein		 CTD PMID:25798061 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573 		JBrowse link
G FOXG1 forkhead box G1 decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of FOXG1 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of FOXG1 mRNA		 CTD PMID:25119042 NCBI chr14:28,766,787...28,770,277
Ensembl chr14:28,764,329...28,770,277 		JBrowse link
G FOXO3 forkhead box O3 multiple interactions
increases expression		 EXP mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of FOXO3 protein]; mirdametinib promotes the reaction [Luteolin results in increased expression of FOXO3 protein]
mirdametinib results in increased expression of FOXO3 protein		 CTD PMID:32268164 NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774 		JBrowse link
G GLRX glutaredoxin multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of GLRX mRNA
mirdametinib results in decreased expression of GLRX mRNA		 CTD PMID:25119042 NCBI chr 5:95,813,849...95,822,726
Ensembl chr 5:95,751,319...95,822,726 		JBrowse link
G GYPC glycophorin C (Gerbich blood group) multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of GYPC mRNA
mirdametinib results in decreased expression of GYPC mRNA		 CTD PMID:25119042 NCBI chr 2:126,656,158...126,696,667
Ensembl chr 2:126,656,133...126,696,667 		JBrowse link
G HAS2 hyaluronan synthase 2 multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of HAS2 mRNA
mirdametinib results in decreased expression of HAS2 mRNA		 CTD PMID:25119042 NCBI chr 8:121,612,116...121,641,440
Ensembl chr 8:121,612,116...121,641,440 		JBrowse link
G HDAC9 histone deacetylase 9 decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of HDAC9 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of HDAC9 mRNA		 CTD PMID:25119042 NCBI chr 7:18,086,825...19,002,416
Ensembl chr 7:18,086,949...19,002,416 		JBrowse link
G HSD17B2 hydroxysteroid 17-beta dehydrogenase 2 multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of HSD17B2 mRNA
mirdametinib results in decreased expression of HSD17B2 mRNA		 CTD PMID:25119042 NCBI chr16:82,035,253...82,098,534
Ensembl chr16:82,035,004...82,098,534 		JBrowse link
G HSF1 heat shock transcription factor 1 decreases activity EXP mirdametinib results in decreased activity of HSF1 protein CTD PMID:34170685 NCBI chr 8:144,291,604...144,314,720
Ensembl chr 8:144,291,591...144,314,720 		JBrowse link
G HTR7 5-hydroxytryptamine receptor 7 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of HTR7 mRNA
mirdametinib results in decreased expression of HTR7 mRNA		 CTD PMID:25119042 NCBI chr10:90,740,823...90,858,039
Ensembl chr10:90,740,823...90,858,039 		JBrowse link
G IFNG interferon gamma multiple interactions EXP mirdametinib inhibits the reaction [[IL15 protein co-treated with IL18 protein] results in increased secretion of IFNG protein]; mirdametinib inhibits the reaction [IL15 protein results in increased secretion of IFNG protein]; mirdametinib inhibits the reaction [IL2 protein results in increased secretion of IFNG protein] CTD PMID:27563819 NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740 		JBrowse link
G IGFBP3 insulin like growth factor binding protein 3 multiple interactions EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of IGFBP3 mRNA CTD PMID:25119042 NCBI chr 7:45,912,245...45,921,272
Ensembl chr 7:45,912,245...45,921,874 		JBrowse link
G IL15 interleukin 15 multiple interactions EXP mirdametinib inhibits the reaction [[IL15 protein co-treated with IL18 protein] results in increased secretion of IFNG protein]; mirdametinib inhibits the reaction [IL15 protein results in increased expression of KLRK1 protein]; mirdametinib inhibits the reaction [IL15 protein results in increased expression of NCR3 protein]; mirdametinib inhibits the reaction [IL15 protein results in increased secretion of IFNG protein] CTD PMID:27563819 NCBI chr 4:141,636,583...141,733,987
Ensembl chr 4:141,636,583...141,733,987 		JBrowse link
G IL18 interleukin 18 multiple interactions EXP mirdametinib inhibits the reaction [[IL15 protein co-treated with IL18 protein] results in increased secretion of IFNG protein] CTD PMID:27563819 NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,253...112,164,096 		JBrowse link
G IL1B interleukin 1 beta multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of IL1B mRNA
mirdametinib results in decreased expression of IL1B mRNA		 CTD PMID:25119042 NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816 		JBrowse link
G IL1RAPL1 interleukin 1 receptor accessory protein like 1 decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of IL1RAPL1 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of IL1RAPL1 mRNA		 CTD PMID:25119042 NCBI chr  X:28,587,446...29,956,718
Ensembl chr  X:28,587,446...29,956,718 		JBrowse link
G IL2 interleukin 2 multiple interactions EXP mirdametinib inhibits the reaction [IL2 protein results in increased expression of KLRK1 protein]; mirdametinib inhibits the reaction [IL2 protein results in increased expression of NCR3 protein]; mirdametinib inhibits the reaction [IL2 protein results in increased secretion of IFNG protein] CTD PMID:27563819 NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725 		JBrowse link
G INHBA inhibin subunit beta A multiple interactions EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of INHBA mRNA CTD PMID:25119042 NCBI chr 7:41,685,114...41,705,406
Ensembl chr 7:41,667,168...41,705,834 		JBrowse link
G ITGA2 integrin subunit alpha 2 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ITGA2 mRNA
mirdametinib results in decreased expression of ITGA2 mRNA		 CTD PMID:25119042 NCBI chr 5:52,989,352...53,094,779
Ensembl chr 5:52,989,340...53,094,779 		JBrowse link
G ITGBL1 integrin subunit beta like 1 multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ITGBL1 mRNA
mirdametinib results in decreased expression of ITGBL1 mRNA		 CTD PMID:25119042 NCBI chr13:101,452,675...101,720,856
Ensembl chr13:101,452,593...101,720,856 		JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit decreases expression ISO mirdametinib results in decreased expression of JUN mRNA CTD PMID:21976371 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048 		JBrowse link
G KIAA1549L KIAA1549 like decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of KIAA1549L mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of KIAA1549L mRNA		 CTD PMID:25119042 NCBI chr11:33,376,108...33,674,102
Ensembl chr11:33,376,108...33,674,102 		JBrowse link
G KIF24 kinesin family member 24 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of KIF24 mRNA
mirdametinib results in decreased expression of KIF24 mRNA		 CTD PMID:25119042 NCBI chr 9:34,252,380...34,333,671
Ensembl chr 9:34,252,380...34,329,268 		JBrowse link
G KIT KIT proto-oncogene, receptor tyrosine kinase multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of KIT mRNA
mirdametinib results in decreased expression of KIT mRNA		 CTD PMID:25119042 NCBI chr 4:54,657,957...54,740,715
Ensembl chr 4:54,657,267...54,740,783 		JBrowse link
G KLRK1 killer cell lectin like receptor K1 multiple interactions EXP mirdametinib inhibits the reaction [IL15 protein results in increased expression of KLRK1 protein]; mirdametinib inhibits the reaction [IL2 protein results in increased expression of KLRK1 protein] CTD PMID:27563819 NCBI chr12:10,372,353...10,390,041
Ensembl chr12:10,372,353...10,391,874 		JBrowse link
G KRAS KRAS proto-oncogene, GTPase multiple interactions EXP
ISO		 KRAS protein affects the reaction [mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [mirdametinib promotes the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [mirdametinib results in decreased expression of MCL1 protein]; KRAS protein affects the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein]; KRAS protein affects the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein]; KRAS protein affects the reaction [mirdametinib results in increased expression of BCL2L11 protein]; KRAS protein affects the reaction [NVP-BKM120 inhibits the reaction [mirdametinib results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [mirdametinib results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [mirdametinib results in increased expression of BCL2L11 protein]]; KRAS protein affects the susceptibility to [[mirdametinib co-treated with NVP-BKM120] results in increased cleavage of PARP1 protein]; KRAS protein affects the susceptibility to [mirdametinib co-treated with NVP-BKM120]
[mirdametinib affects the susceptibility to KRAS protein] affects the reaction [NVP-BKM120 results in decreased expression of MKI67 protein]		 CTD PMID:24576621 NCBI chr12:25,205,246...25,250,929
Ensembl chr12:25,205,246...25,250,936 		JBrowse link
G LPL lipoprotein lipase multiple interactions EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of LPL mRNA CTD PMID:25119042 NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259 		JBrowse link
G LPXN leupaxin multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of LPXN mRNA
mirdametinib results in decreased expression of LPXN mRNA		 CTD PMID:25119042 NCBI chr11:58,526,871...58,578,891
Ensembl chr11:58,526,871...58,578,220 		JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions EXP mirdametinib inhibits the reaction [Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein] CTD PMID:32268164 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779 		JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions ISO mirdametinib inhibits the reaction [polyphyllin I inhibits the reaction [Dietary Fats results in decreased expression of MAP2K1 protein]] CTD PMID:36120828 NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,837...66,491,656 		JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 multiple interactions ISO mirdametinib inhibits the reaction [polyphyllin I inhibits the reaction [Dietary Fats results in decreased expression of MAP2K2 protein]] CTD PMID:36120828 NCBI chr19:4,090,321...4,124,122
Ensembl chr19:4,090,321...4,124,122 		JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions
decreases phosphorylation		 EXP
ISO		 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein]; [mirdametinib co-treated with silmitasertib] results in decreased phosphorylation of MAPK1 protein; [MK 2206 co-treated with mirdametinib] results in decreased phosphorylation of MAPK1 protein; dactolisib promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein]; KRAS protein affects the reaction [mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein]; KRAS protein affects the reaction [NVP-BKM120 inhibits the reaction [mirdametinib results in increased phosphorylation of MAPK1 protein]]; mirdametinib inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]; mirdametinib promotes the reaction [Axitinib results in decreased phosphorylation of MAPK1 protein]; mirdametinib promotes the reaction [pazopanib results in decreased phosphorylation of MAPK1 protein]; mirdametinib promotes the reaction [Sunitinib results in decreased phosphorylation of MAPK1 protein]
mirdametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK1 protein]
mirdametinib inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [polyphyllin I inhibits the reaction [Dietary Fats results in decreased expression of MAPK1 protein]]		 CTD PMID:21996734 PMID:22415236 PMID:23872713 PMID:24011934 PMID:24576621 More... NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680 		JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions
decreases phosphorylation		 EXP
ISO		 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein]; [mirdametinib co-treated with silmitasertib] results in decreased phosphorylation of MAPK3 protein; [MK 2206 co-treated with mirdametinib] results in decreased phosphorylation of MAPK3 protein; dactolisib promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein]; KRAS protein affects the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein]; mirdametinib inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of MAPK3 protein]; mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK3 protein]; mirdametinib promotes the reaction [Axitinib results in decreased phosphorylation of MAPK3 protein]; mirdametinib promotes the reaction [pazopanib results in decreased phosphorylation of MAPK3 protein]; mirdametinib promotes the reaction [Sunitinib results in decreased phosphorylation of MAPK3 protein]
mirdametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]; mirdametinib inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK3 protein]
mirdametinib inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK3 protein]; mirdametinib inhibits the reaction [polyphyllin I inhibits the reaction [Dietary Fats results in decreased expression of MAPK3 protein]]		 CTD PMID:21996734 PMID:22415236 PMID:23872713 PMID:24011934 PMID:24576621 More... NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506 		JBrowse link
G MCL1 MCL1 apoptosis regulator, BCL2 family member increases expression
decreases expression
multiple interactions		 EXP mirdametinib results in increased expression of MCL1 protein
mirdametinib results in decreased expression of MCL1 protein
[mirdametinib co-treated with MK 2206] results in increased expression of MCL1 protein; [romidepsin co-treated with mirdametinib co-treated with MK 2206] results in increased expression of MCL1 protein; [romidepsin co-treated with mirdametinib] results in increased expression of MCL1 protein; KRAS protein affects the reaction [mirdametinib promotes the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [mirdametinib results in decreased expression of MCL1 protein]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [mirdametinib results in decreased expression of MCL1 protein]]; mirdametinib promotes the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]; NVP-BKM120 promotes the reaction [mirdametinib results in decreased expression of MCL1 protein]		 CTD PMID:24576621 PMID:27634878 NCBI chr 1:150,574,558...150,579,610
Ensembl chr 1:150,560,895...150,579,738 		JBrowse link
G MGLL monoglyceride lipase multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of MGLL mRNA
mirdametinib results in decreased expression of MGLL mRNA		 CTD PMID:25119042 NCBI chr 3:127,689,066...127,823,185
Ensembl chr 3:127,689,062...128,052,190 		JBrowse link
G MKI67 marker of proliferation Ki-67 multiple interactions ISO [mirdametinib affects the susceptibility to KRAS protein] affects the reaction [NVP-BKM120 results in decreased expression of MKI67 protein]; mirdametinib inhibits the reaction [camostat results in increased expression of MKI67 protein] CTD PMID:24576621 PMID:25104499 NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423 		JBrowse link
G MMD monocyte to macrophage differentiation associated multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of MMD mRNA
mirdametinib results in decreased expression of MMD mRNA		 CTD PMID:25119042 NCBI chr17:55,392,622...55,421,835
Ensembl chr17:55,392,622...55,421,924 		JBrowse link
G MMP1 matrix metallopeptidase 1 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of MMP1 mRNA
mirdametinib results in decreased expression of MMP1 mRNA		 CTD PMID:25119042 NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160 		JBrowse link
G MMP10 matrix metallopeptidase 10 multiple interactions EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of MMP10 mRNA CTD PMID:25119042 NCBI chr11:102,770,502...102,780,628
Ensembl chr11:102,770,502...102,780,628 		JBrowse link
G MTOR mechanistic target of rapamycin kinase multiple interactions ISO mirdametinib inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK3 protein] CTD PMID:29384525 NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556 		JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor multiple interactions
decreases expression		 EXP (+)-JQ1 compound promotes the reaction [mirdametinib results in decreased expression of MYC protein]; mirdametinib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein] CTD PMID:26284497 NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951 		JBrowse link
G NAV3 neuron navigator 3 decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of NAV3 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of NAV3 mRNA		 CTD PMID:25119042 NCBI chr12:77,571,862...78,213,010
Ensembl chr12:77,324,641...78,213,010 		JBrowse link
G NCR3 natural cytotoxicity triggering receptor 3 multiple interactions EXP mirdametinib inhibits the reaction [IL15 protein results in increased expression of NCR3 protein]; mirdametinib inhibits the reaction [IL2 protein results in increased expression of NCR3 protein] CTD PMID:27563819 NCBI chr 6:31,588,895...31,593,006
Ensembl chr 6:31,588,895...31,593,006 		JBrowse link
G NF1 neurofibromin 1 multiple interactions EXP NF1 protein inhibits the reaction [SUZ12 gene mutant form results in increased susceptibility to [(+)-JQ1 compound co-treated with mirdametinib]] CTD PMID:25119042 NCBI chr17:31,094,927...31,377,677
Ensembl chr17:31,094,927...31,382,116 		JBrowse link
G NME5 NME/NM23 family member 5 multiple interactions EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of NME5 mRNA CTD PMID:25119042 NCBI chr 5:138,115,175...138,139,428
Ensembl chr 5:138,115,175...138,139,443 		JBrowse link
G NR0B2 nuclear receptor subfamily 0 group B member 2 decreases expression EXP mirdametinib results in decreased expression of NR0B2 mRNA CTD PMID:24819614 NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975 		JBrowse link
G NRCAM neuronal cell adhesion molecule decreases expression EXP mirdametinib results in decreased expression of NRCAM mRNA CTD PMID:25119042 NCBI chr 7:108,147,649...108,456,720
Ensembl chr 7:108,147,623...108,456,717 		JBrowse link
G NRP1 neuropilin 1 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of NRP1 mRNA
mirdametinib results in decreased expression of NRP1 mRNA		 CTD PMID:25119042 NCBI chr10:33,177,493...33,334,667
Ensembl chr10:33,177,492...33,336,262 		JBrowse link
G NTM neurotrimin multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of NTM mRNA
mirdametinib results in decreased expression of NTM mRNA		 CTD PMID:25119042 NCBI chr11:131,370,615...132,336,822
Ensembl chr11:131,370,478...132,336,822 		JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 increases cleavage
multiple interactions		 EXP mirdametinib results in increased cleavage of PARP1 protein
[mirdametinib co-treated with MK 2206] results in increased cleavage of PARP1 protein; [mirdametinib co-treated with NVP-BKM120] results in increased cleavage of PARP1 protein; KRAS protein affects the susceptibility to [[mirdametinib co-treated with NVP-BKM120] results in increased cleavage of PARP1 protein]; mirdametinib promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; romidepsin promotes the reaction [[mirdametinib co-treated with MK 2206] results in increased cleavage of PARP1 protein]; romidepsin promotes the reaction [mirdametinib results in increased cleavage of PARP1 protein]		 CTD PMID:24576621 PMID:27634878 PMID:32268164 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154 		JBrowse link
G PCNA proliferating cell nuclear antigen multiple interactions ISO mirdametinib inhibits the reaction [camostat results in increased expression of PCNA protein] CTD PMID:25104499 NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626 		JBrowse link
G PDCD1LG2 programmed cell death 1 ligand 2 multiple interactions EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of PDCD1LG2 mRNA CTD PMID:25119042 NCBI chr 9:5,510,531...5,571,282
Ensembl chr 9:5,510,531...5,571,282 		JBrowse link
G PEG3 paternally expressed 3 decreases expression EXP mirdametinib results in decreased expression of PEG3 mRNA CTD PMID:25119042 NCBI chr19:56,810,082...56,840,726
Ensembl chr19:56,810,077...56,840,728 		JBrowse link
G PLAU plasminogen activator, urokinase multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of PLAU mRNA
mirdametinib results in decreased expression of PLAU mRNA		 CTD PMID:25119042 NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496 		JBrowse link
G PLAUR plasminogen activator, urokinase receptor multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of PLAUR mRNA
mirdametinib results in decreased expression of PLAUR mRNA		 CTD PMID:25119042 NCBI chr19:43,646,095...43,670,169
Ensembl chr19:43,646,095...43,670,547 		JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions ISO mirdametinib inhibits the reaction [Protein Kinase Inhibitors results in increased phosphorylation of and results in decreased activity of PPARG protein] CTD PMID:26670611 NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356 		JBrowse link
G PRDM1 PR/SET domain 1 decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of PRDM1 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of PRDM1 mRNA		 CTD PMID:25119042 NCBI chr 6:105,992,690...106,109,938
Ensembl chr 6:105,993,463...106,109,939 		JBrowse link
G PRRX1 paired related homeobox 1 multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of PRRX1 mRNA
mirdametinib results in decreased expression of PRRX1 mRNA		 CTD PMID:25119042 NCBI chr 1:170,662,768...170,739,421
Ensembl chr 1:170,662,728...170,739,421 		JBrowse link
G PTX3 pentraxin 3 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of PTX3 mRNA
mirdametinib results in decreased expression of PTX3 mRNA		 CTD PMID:25119042 NCBI chr 3:157,436,850...157,443,633
Ensembl chr 3:157,436,850...157,443,633 		JBrowse link
G RAC1 Rac family small GTPase 1 affects response to substance EXP RAC1 protein alternative form affects the susceptibility to mirdametinib CTD PMID:23033341 NCBI chr 7:6,374,527...6,403,967
Ensembl chr 7:6,374,527...6,403,967 		JBrowse link
G RELN reelin decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of RELN mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of RELN mRNA		 CTD PMID:25119042 NCBI chr 7:103,471,789...103,989,658
Ensembl chr 7:103,471,381...103,989,658 		JBrowse link
G RPS6 ribosomal protein S6 multiple interactions
decreases phosphorylation		 EXP 2-amino-8-(4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido(2,3-d)pyrimidin-7(8H)-one promotes the reaction [mirdametinib results in decreased phosphorylation of RPS6 protein]; mirdametinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in decreased phosphorylation of RPS6 protein]; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of RPS6 protein]; mirdametinib promotes the reaction [NVP-BKM120 results in decreased phosphorylation of RPS6 protein] CTD PMID:22415236 PMID:24011934 PMID:24576621 NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236 		JBrowse link
G SCG5 secretogranin V multiple interactions EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of SCG5 mRNA CTD PMID:25119042 NCBI chr15:32,641,710...32,697,092
Ensembl chr15:32,641,676...32,697,098 		JBrowse link
G SEMA3A semaphorin 3A multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SEMA3A mRNA
mirdametinib results in decreased expression of SEMA3A mRNA		 CTD PMID:25119042 NCBI chr 7:83,955,777...84,492,725
Ensembl chr 7:83,955,777...84,492,724 		JBrowse link
G SIGLEC15 sialic acid binding Ig like lectin 15 multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of SIGLEC15 mRNA
mirdametinib results in decreased expression of SIGLEC15 mRNA		 CTD PMID:25119042 NCBI chr18:45,825,675...45,844,094
Ensembl chr18:45,825,675...45,844,094 		JBrowse link
G SLC6A15 solute carrier family 6 member 15 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SLC6A15 mRNA
mirdametinib results in decreased expression of SLC6A15 mRNA		 CTD PMID:25119042 NCBI chr12:84,859,491...84,912,799
Ensembl chr12:84,859,491...84,913,629 		JBrowse link
G SLIT2 slit guidance ligand 2 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SLIT2 mRNA
mirdametinib results in decreased expression of SLIT2 mRNA		 CTD PMID:25119042 NCBI chr 4:20,251,905...20,620,561
Ensembl chr 4:20,251,905...20,620,561 		JBrowse link
G SOX9 SRY-box transcription factor 9 decreases expression EXP mirdametinib results in decreased expression of SOX9 mRNA CTD PMID:25119042 NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416 		JBrowse link
G SPP1 secreted phosphoprotein 1 multiple interactions EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SPP1 mRNA CTD PMID:25119042 NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532 		JBrowse link
G SPRY2 sprouty RTK signaling antagonist 2 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SPRY2 mRNA
mirdametinib results in decreased expression of SPRY2 mRNA		 CTD PMID:25119042 NCBI chr13:80,335,976...80,341,126
Ensembl chr13:80,335,976...80,341,126 		JBrowse link
G ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ST3GAL6 mRNA
mirdametinib results in decreased expression of ST3GAL6 mRNA		 CTD PMID:25119042 NCBI chr 3:98,732,262...98,795,852
Ensembl chr 3:98,732,236...98,821,201 		JBrowse link
G STC1 stanniocalcin 1 decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of STC1 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of STC1 mRNA		 CTD PMID:25119042 NCBI chr 8:23,841,929...23,854,806
Ensembl chr 8:23,841,929...23,854,806 		JBrowse link
G STX1A syntaxin 1A multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of STX1A mRNA
mirdametinib results in decreased expression of STX1A mRNA		 CTD PMID:25119042 NCBI chr 7:73,699,210...73,719,669
Ensembl chr 7:73,699,206...73,719,672 		JBrowse link
G SUZ12 SUZ12 polycomb repressive complex 2 subunit multiple interactions EXP NF1 protein inhibits the reaction [SUZ12 gene mutant form results in increased susceptibility to [(+)-JQ1 compound co-treated with mirdametinib]]; SUZ12 gene mutant form results in increased susceptibility to [(+)-JQ1 compound co-treated with mirdametinib] CTD PMID:25119042 NCBI chr17:31,937,007...32,001,038
Ensembl chr17:31,937,007...32,001,038 		JBrowse link
G SYNGAP1 synaptic Ras GTPase activating protein 1 affects response to substance ISO SYNGAP1 protein affects the susceptibility to mirdametinib CTD PMID:29940508 NCBI chr 6:33,418,167...33,453,689
Ensembl chr 6:33,419,661...33,453,689 		JBrowse link
G TBX3 T-box transcription factor 3 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of TBX3 mRNA
mirdametinib results in decreased expression of TBX3 mRNA		 CTD PMID:25119042 NCBI chr12:114,670,255...114,684,175
Ensembl chr12:114,670,255...114,684,175 		JBrowse link
G TFPI tissue factor pathway inhibitor multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of TFPI mRNA
mirdametinib results in decreased expression of TFPI mRNA		 CTD PMID:25119042 NCBI chr 2:187,464,230...187,554,435
Ensembl chr 2:187,464,230...187,565,760 		JBrowse link
G TGM2 transglutaminase 2 multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of TGM2 mRNA
mirdametinib results in decreased expression of TGM2 mRNA		 CTD PMID:25119042 NCBI chr20:38,127,385...38,168,475
Ensembl chr20:38,127,385...38,166,578 		JBrowse link
G TLR4 toll like receptor 4 decreases expression
multiple interactions		 EXP mirdametinib results in decreased expression of TLR4 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of TLR4 mRNA		 CTD PMID:25119042 NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735 		JBrowse link
G TMEM156 transmembrane protein 156 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of TMEM156 mRNA
mirdametinib results in decreased expression of TMEM156 mRNA		 CTD PMID:25119042 NCBI chr 4:38,966,744...39,032,409
Ensembl chr 4:38,966,744...39,032,922 		JBrowse link
G TNFSF15 TNF superfamily member 15 multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of TNFSF15 mRNA
mirdametinib results in decreased expression of TNFSF15 mRNA		 CTD PMID:25119042 NCBI chr 9:114,784,635...114,806,039
Ensembl chr 9:114,784,652...114,806,039 		JBrowse link
G TP53 tumor protein p53 multiple interactions ISO [mirdametinib co-treated with MK 2206] results in increased expression of and results in increased phosphorylation of TRP53 protein CTD PMID:28691888 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546 		JBrowse link
G TRIB2 tribbles pseudokinase 2 multiple interactions
decreases expression		 EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of TRIB2 mRNA
mirdametinib results in decreased expression of TRIB2 mRNA		 CTD PMID:25119042 NCBI chr 2:12,716,936...12,742,734
Ensembl chr 2:12,716,910...12,742,734 		JBrowse link
G UCP1 uncoupling protein 1 multiple interactions EXP mirdametinib inhibits the reaction [Protein Kinase Inhibitors inhibits the reaction [FASN protein results in increased expression of UCP1 protein]] CTD PMID:26670611 NCBI chr 4:140,559,431...140,568,961
Ensembl chr 4:140,559,431...140,568,961 		JBrowse link
G UGT8 UDP glycosyltransferase 8 multiple interactions EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of UGT8 mRNA CTD PMID:25119042 NCBI chr 4:114,598,402...114,678,225
Ensembl chr 4:114,598,770...114,678,225 		JBrowse link
G VEGFC vascular endothelial growth factor C multiple interactions
decreases expression		 EXP [(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of VEGFC mRNA
mirdametinib results in decreased expression of VEGFC mRNA		 CTD PMID:25119042 NCBI chr 4:176,683,538...176,792,922
Ensembl chr 4:176,683,538...176,792,922 		JBrowse link
G ZEB1 zinc finger E-box binding homeobox 1 multiple interactions EXP [mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ZEB1 mRNA CTD PMID:25119042 NCBI chr10:31,318,417...31,529,804
Ensembl chr10:31,318,495...31,529,814 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 26050
    role 25966
      application 25188
        pharmaceutical 24562
          drug 24559
            antineoplastic agent 20861
              PD 0325901 135
Path 2
Term Annotations click to browse term
  CHEBI ontology 26050
    subatomic particle 26025
      composite particle 26025
        hadron 26025
          baryon 26025
            nucleon 26025
              atomic nucleus 26025
                atom 26025
                  main group element atom 25850
                    p-block element atom 25850
                      carbon group element atom 25447
                        carbon atom 25405
                          organic molecular entity 25405
                            heteroorganic entity 24781
                              organochalcogen compound 24394
                                organooxygen compound 24071
                                  carbon oxoacid 22773
                                    carboxylic acid 22753
                                      carboacyl group 20066
                                        univalent carboacyl group 20066
                                          carbamoyl group 19580
                                            carboxamide 19580
                                              hydroxamic acid 6718
                                                hydroxamic acid ester 155
                                                  PD 0325901 135
paths to the root